It is a modular urinalysis workflow launched by DIRUI, which can meet the realistic needs of clinical laboratories for automated and high-throughput urine testing.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

French diagnostics maker BioMérieux said on Tuesday that it has received CE marking for its Vidas Kube automated immunoassay system.

Meihua Medical completes Series B financing of over CNY 100 Million, committed to building a superior brand in microbiology testing. Non-invasive cancer early screening company OneGene completes tens of millions of CNY Series B financing.

Chinese cancer diagnostics firm SeekIn said Monday that it has received the CE mark for its PanCanSeek Cancer Mutation Detection Kit and now intends to market the test in the European Union and other regions that recognize the designation.

Medtronic said in October it plans to divest its patient monitoring and respiratory interventions businesses.

Recently, Shenzhen Superbio Technology Co., Ltd. Fentanyl Drug Abuse Detection Kit (fluorescence chromatography method) has obtained 510 (k) pre-market notification, which is the world's first POCT product approved by the US FDA for the detection of fentanyl by fluorescence method.

The American College of Medical Genetics and Genomics strongly recommends noninvasive prenatal screening (NIPS) over other screening approaches for detecting common fetal trisomies for all pregnant patients, according to new practice guidelines published on Friday.

QuidelOrtho said on Friday that it has signed a definitive agreement to form a joint venture (JV) between its China-based Ortho Clinical Diagnostics Trading subsidiary and Shanghai Medconn Biotechnology, a subsidiary of Shanghai Runda Medical Technology (Runda Medical).

On December 14, 2022, Autobio and Pushkang signed a strategic cooperation agreement in Zhengzhou, and the two sides will again open in-depth cooperation in the field of blood coagulation testing.

Cofactor Genomics on Wednesday announced the commencement of a study of its OncoPrism assay in non-small cell lung cancer (NSCLC).

New research suggests that a subset of late-onset cerebellar ataxia cases may be caused by repeat expansions involving the fibroblast growth factor 14-coding gene FGF14.